NAMS (NewAmsterdam Pharma Co NV) Moat Score: 6/10 (As of Aug. 08, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NAMS NewAmsterdam Pharma Co NV NAMS
45 GF Score
Price $27.96
GF Value $10.42
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is NewAmsterdam Pharma Co NV Moat Score?

NewAmsterdam Pharma Co NV NAMS +1.05% 45 Moat Score is 6 as of Aug. 08, 2026. GuruFocus rates NAMS with a GF Score™ of 45/100 and a GF Value™ of $10.42 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 1,393 Biotechnology companies, NewAmsterdam Pharma Co NV ranks better than 98.92% on this metric.

NewAmsterdam Pharma Co NV has the Moat Score of 6, which implies that the company might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

NewAmsterdam Pharma Co NV has Narrow Moat: NewAmsterdam Pharma has a strong narrow moat due to its valuable patents and consistent R&D capabilities. It benefits from regulatory barriers in the pharmaceutical industry, but lacks the scale or network effects for a wide moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes NewAmsterdam Pharma Co NV might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

NewAmsterdam Pharma Co NV  (NAS:NAMS) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

NewAmsterdam Pharma Co NV Moat Score Related Terms

NAMS vs ARQT, IDYA, ALMS: Moat Score Comparison

For the Biotechnology subindustry, NewAmsterdam Pharma Co NV's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NewAmsterdam Pharma Co NV Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NewAmsterdam Pharma Co NV's Moat Score distribution charts can be found below:

* The bar in red indicates where NewAmsterdam Pharma Co NV's Moat Score falls into.


NAMS
45GF Score
NewAmsterdam Pharma Co NV NAMS
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 6 mean?
NewAmsterdam Pharma Co NV (NAMS) has a Moat Score of 6 as of Aug. 08, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, NewAmsterdam Pharma Co NV ranks #15 out of 1393 companies in the Biotechnology industry, placing it in the top 1.1%.
Is NewAmsterdam Pharma Co NV's Moat Score too high?
NewAmsterdam Pharma Co NV's current Moat Score is 6. The Biotechnology industry median Moat Score is 2.00. NewAmsterdam Pharma Co NV's value of 6 is 200% above this industry median. Based on the distribution chart, NewAmsterdam Pharma Co NV ranks #15 out of 1393 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, NewAmsterdam Pharma Co NV has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NewAmsterdam Pharma Co NV's Moat Score compare to ARQT and IDYA?
According to the Biotechnology industry distribution chart, NewAmsterdam Pharma Co NV ranks #15 out of 1393 companies for Moat Score. This places NewAmsterdam Pharma Co NV in the top 1% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. NewAmsterdam Pharma Co NV's value of 6 is 200% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,393 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NewAmsterdam Pharma Co NV's current Moat Score of 6 is 200% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NewAmsterdam Pharma Co NV's current Moat Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NewAmsterdam Pharma Co NV stock overvalued right now?
Based on GuruFocus' analysis, NewAmsterdam Pharma Co NV (NAMS) is currently considered Significantly Overvalued. The stock's GF Value™ is $10.42, compared to a current price of $27.96 — trading 168.3% above its estimated fair value. The current Moat Score is 6 and 200% above the Biotechnology industry median of 2.00. NewAmsterdam Pharma Co NV's overall GF Score™ is 45/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For NewAmsterdam Pharma Co NV (NAMS), the current Moat Score is 6 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NewAmsterdam Pharma Co NV (NAMS) Overvalued in 2026?

Based on GuruFocus' analysis, NewAmsterdam Pharma Co NV stock appears to be overvalued. The current stock price of $27.96 is trading 168.3% above its estimated GF Value™ of $10.42. GuruFocus considers NewAmsterdam Pharma Co NV to be Significantly Overvalued.

Key valuation signals for NAMS:

  • Moat Score: 6
  • GF Value™: $10.42 vs. price of $27.96 (168.3% above fair value)
  • GF Score™: 45/100 with 3 warning signs
  • Industry Position: 200% above the Biotechnology median (#15 of 1393)

No single metric tells the full story. See the NAMS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

NewAmsterdam Pharma Co NV Business Description

Other Exchanges KH6:Germany
Address Gooimeer 2-35, Naarden, NH, NLD, 1411 DC
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
45GF Score

Get the complete analysis for NAMS

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$27.96
Price
$10.42
GF Value